Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma.
Michael FrickerJohn HarringtonSarah A HilesPeter G GibsonPublished in: Allergy (2024)
Mepolizumab depletes iEOs and reduces circulating eosinophil viability in severe asthma but preserves a residual population of circulatory hEOs. In contrast benralizumab depleted both iEOs and hEOs. Higher iEO abundance and eosinophil viability are associated with poorer clinical outcomes following mepolizumab-treatment. Monitoring circulating eosinophil phenotype and viability may be useful to predict biologic treatment response in severe asthma.